Rentokil jumps as US pest control momentum improves

Rentokil shares jumped 9.2% after FY results roughly in line with City consensus: revenue from continuing operations rose 4.4% to $6.9bn and adjusted operating profit increased 5.4% to $1.1bn. Free cash flow surged 24.5% to $615m with 98% cash conversion, net debt fell to $3.65bn (from $4.0bn) and a final dividend of 8.24 cents (12.39 cents total, +3%) was declared. Management highlighted accelerating North American pest-control momentum (organic growth improved from 0.1% H1 to 2.6% in Q4) and reiterated 2026 guidance in line with market expectations while targeting a North America operating margin above 20% by 2027; CEO Andy Ransom will step down this month.

Analysis

Market structure: Rentokil (RTO) is a clear winner—global scale, 98% cash conversion and falling net debt give it superior free-cash-flow optionality to out-invest smaller independents and buy market share in North America where organic growth accelerated to 2.6% in Q4. Suppliers of pesticide formulations and B2B facilities-service software could see upside demand; small local operators and low-cash peers are the losers if consolidation accelerates. Improved cash flow and deleveraging should tighten Rentokil credit spreads and modestly compress implied equity volatility versus peers over 6–12 months.

Risk assessment: Key tail risks are regulatory action on active ingredients, a botched CEO transition this month, and another severe-weather disruption in NA (a single harsh winter month could swing near-term organic growth ±200–300bp). Immediate risk (days) is profit-taking after a 9% pop; short-term (weeks–months) hinges on Q1 trading and weather; long-term (2026–27) execution risk centers on delivering >20% NA margin by 2027 and sustaining pricing without customer churn. Hidden dependencies include franchise/channel economics and fuel/labor cost pass-through clauses.

Trade implications: Favor a tactical overweight to RTO sized 2–3% of equity portfolio on a 12–18 month horizon (target ~600p, stop 380p), and use a defined-cost options spread to lever upside (see decisions). Run a relative-value pair: long RTO vs short ROL (Rollins, NYSE:ROL) 1:1 for 9–12 months to capture superior margin/leverage optionality. Rotate 2–4% from highly cyclical retail/consumer discretionary into defensive business-services (RTO, Ecolab ECL) over next 3 months.

Contrarian angles: Consensus underweights management risk—the CEO exit could delay margin programmes meaningfully if the successor reprioritises M&A or capital allocation. The market may be underpricing downside from regulatory pesticide restrictions or aggressive competitor pricing that compresses gross margins by 200–400bp. Historically, service rollups show early-year pops on cash flow beats but often plateau if execution stalls—set hard milestone checks (Q1 trading, new CEO plan) before adding size.

Key Decisions for Investors

• Establish a 2–3% long position in Rentokil (RTO) on London close or better; target price 600p over 12–18 months (≈+29% from 464.6p), initial hard stop at 380p (-18%) and trim 50% at 540p to lock gains if margin guidance stalls.
• Implement a 1–1 pair trade: long RTO (1.5% portfolio) vs short Rollins (NYSE:ROL, 1.5%) for 9–12 months to capture relative margin expansion; cover the short if ROL reports organic growth >5% QoQ or RTO misses 2026 guidance by >150bp.
• Buy a 12‑month RTO call spread to lever upside with defined risk: buy 12‑month 460p call and sell 12‑month 560p call, sizing to 0.75–1.0% of portfolio notional; this caps maximum premium outlay while participating to the 600p target.
• If deploying >3% equity exposure to RTO, hedge tail downside with bought 12‑month 380p puts sized to 50% of the long equity notional; reassess hedge necessity after the new CEO outlines a 90‑day execution plan.
• Reallocate 2–4% from cyclical retail and discretionary (e.g., selected retail REITs) into defensive service names RTO and Ecolab (NYSE:ECL) over the next 6–12 weeks to lock in recurring revenue and superior cash conversion.